Recombinant proteins and antibodies add manufacturing complexity and batch variability.
Dengue-first product path
From epitope prediction to assay-ready evidence.
UbiqueBio connects target selection, computational design, synthetic libraries and ELISA validation into focused diagnostic packages for partners.
Synthetic recognition elements
Antibody and antigen diagnostics
Mexico / LATAM validation
Validation workflow
Peptide panel screening
Candidate ranking
Assay optimization
Partner-ready package
Problem
Diagnostic access is constrained by the recognition element, not only the test format.
The bottleneck is the biological reagent layer: expensive to produce, hard to standardize, fragile to distribute and slow to redesign when pathogen biology changes.
Biological reagent bottleneck
cost · variability · stability · redesign time
Cold-chain and stability constraints limit decentralized access.
New pathogens and variants need faster target-to-candidate cycles.
Solution / Platform
Design the recognition element. Validate the assay.
A focused workflow from pathogen target to synthetic candidate and assay readout.
Choose pathogen proteins and clinical question.
Rank peptide and aptamer candidates in silico.
Build focused synthetic recognition libraries.
Optimize ELISA or rapid-test prototype readouts.
Lead program
One focused product path first: Dengue IgG ELISA.
We are prioritizing a partner-ready Dengue antibody ELISA package for Mexico/LATAM validation before expanding the platform into antigen capture and rapid-test formats.
Now
Dengue IgG ELISA
First product milestone: optimize synthetic peptide candidates, standardize assay conditions and generate a clearer validation package for diagnostic partners.
LATAM beachhead
Mexico validation path
Partner-ready data package
DNA aptamer screening remains the route toward a future rapid-test path after the ELISA milestone is de-risked.
Existing sera-based work supports the broader synthetic peptide immunodiagnostic thesis.
Additional targets are staged as platform extensions, not distractions from the first funded milestone.
Evidence
A platform grounded in data, chemistry and published precedent.
Business model
Synthetic reagents and assay-ready packages for diagnostic partners.
UbiqueBio licenses synthetic recognition elements and supporting data packages to diagnostic manufacturers, healthcare companies, hospitals, NGOs and public-health programs.
Synthetic peptide / aptamer reagent
Validation data package
ELISA or rapid-test prototype
Company
US company, LATAM execution.
A Delaware corporation built for U.S. commercial partnering, with a Mexico validation path and Argentina R&D operations.
Delaware C-Corp structure for financing, governance and global diagnostic partnerships.
INSP-linked path for Dengue assay validation, sample access and LATAM clinical relevance.
Ubique Biotech Argentina SAU supports research, development and regional execution.
Contact
Partnerships, licensing and diagnostic development.
For product, partnership, customer or investor inquiries, contact the UbiqueBio team.